Outlines broad discovery and development efforts targeting synthetic lethality and DNA-damage repair mechanisms, including PRMT5-MTA, SGR-3515 and SGR-2921 programs NEW YORK--(BUSINESS ...
TOKYO, Oct. 8, 2024 /PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO: Toshio Fujimoto, "Ciconia") today announced its establishment as a joint venture company based on a ...
New service offering enables GR/NF-κB transrepression studies to support deeper mechanism-of-action insight in drug ...
Alloy Therapeutics, a leading biotechnology ecosystem company, today announced a strategic collaboration with the Institute ...
PARIS & LONDON--(BUSINESS WIRE)--Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled generative AI engine. Building on successes in ...
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the ...
Invivyd, Inc. has launched a discovery program for a monoclonal antibody (mAb) targeting measles, following requests from healthcare providers for a treatment option for active infections and ...
Scientific progress often stalls not because of a lack of ideas, but because of a lack of material. Across drug discovery, agriculture, and industrial biotech, promising programs are delayed or ...
CU Science Discovery high school programs build connections between university science and the broader community. Through authentic, hands-on experiences with CU researchers, these programs spark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results